<DOC>
	<DOCNO>NCT02381080</DOCNO>
	<brief_summary>The purpose study assess effect moderate Cytochrome P450 ( CYP ) 3A inhibitor ( erythromycin ) strong CYP3A inhibitor ( voriconazole ) steady-state pharmacokinetics ( PK [ study way drug enters leave blood tissue time ] ) repeat oral dos ibrutinib participant B-cell malignancy ( cancer progressively enlarge spread tumor ) .</brief_summary>
	<brief_title>Interaction Study Ibrutinib Cytochrome P450 ( CYP ) 3A Inhibitors Participants With B-cell Malignancy</brief_title>
	<detailed_description>This open-label ( participant researcher aware treatment participant receive ) , multi-center ( 1 hospital medical school team work medical research study ) , drug-drug interaction ( DDI ) study ibrutinib moderate strong CYP3A inhibitor ( erythromycin voriconazole respectively ) participant B-cell malignancy ( include Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma [ CLL/SLL ] , Follicular Lymphoma [ FL ] , Marginal Zone Lymphoma [ MZL ] , Waldenstrom 's Macroglobulinemia [ WM ] Mantle Cell Lymphoma [ MCL ] ) . The study consist Screening Phase ( 28 day ) , Treatment Phase ( consist six 28-days cycle ) , End-of-Treatment ( EoT ) Visit ( within 30 day last dose study drug ) . The study consist 2 Parts . In Part 1 , extent DDI ibrutinib dose level 140 milligram ( mg ) CYP3A inhibitor assess . After completion Part 1 study , interim analysis available PK safety data conduct Part 2 perform observed drug interaction less anticipate base current information . In Part 2 , safety PK ibrutinib dose level 560 mg administer CYP3A inhibitor assess . Participants continue derive clinical benefit ibrutinib treatment end study , eligible continue PCI-32765CAN3001 study ( NCT01804686 ) end participation trial , EoT visit complete , continue receive ibrutinib part PCI-32765CAN3001 protocol . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<criteria>Histologically cytologically confirm Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma ( CLL/SLL ) , Marginal Zone Lymphoma ( MZL ) , Mantle Cell Lymphoma ( MCL ) , Follicular Lymphoma ( FL ) , Waldenstrom 's Macroglobulinemia ( WM ) Relapsed refractory disease least 1 prior line systemic therapy ( participant FL MZL must fail antiCD20 monoclonal antibody contain chemotherapy regimen ) Eastern Cooperative Oncology Group Performance Status score 0 1 Hematology value within follow limit : ) Absolute neutrophil count ( ANC ) great equal ( &gt; = ) 1.0*10^9 per liter ( L ) ; b ) Platelets &gt; =50*10^9/L without transfusion support within 7 day ; c ) Hemoglobin &gt; =8 gram per deciliter ( g/dL ) without transfusion support within 7 day ; ) Prothrombin time /International normalize ratio ( PT/INR ) less equal ( &lt; = ) 1.5*Upper Limit Normal ( ULN ) activate partial thromboplastin time ( aPTT ) &lt; =1.5*ULN Biochemical value within follow limit : ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; =3.0*ULN ; b ) Total bilirubin &lt; =1.5*ULN ( unless due Gilbert 's syndrome ) ; c ) Serum creatinine &lt; =1.5*ULN calculate creatinine clearance &gt; =50 milliliter per minute per 1.73 square meter Major surgery within 4 week first dose ibrutinib Diagnosed treated malignancy indication study except : ) Adequately treat nonmelanoma skin cancer lentigo maligna , curatively treated insitu cancer without evidence disease ; b ) Malignancy treat curative intent know active disease present &gt; =3 year first dose ibrutinib History stroke intracranial hemorrhage within 6 month prior first dose ibrutinib History galactose intolerance Requires anticoagulation warfarin equivalent vitamin K antagonist ( example , phenprocoumon )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>B-Cell Chronic Lymphocytic Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Marginal Zone Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Waldenstrom 's Macroglobulinemia</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>IMBRUVICA</keyword>
	<keyword>PCI-32765</keyword>
	<keyword>JNJ-54179060</keyword>
</DOC>